A 24-week double blind treatment and 24-week follow up, randomized, multi-center, placebo-controlled, phase IIa/IIb study to evaluate the safety and efficacy of i.v. bimagrumab on total lean body mass and physical performance in patients after surgical treatment of hip fracture

1st June 2017 - ongoing

Status: Active

Specialism: Liver.

Team:

PI: Opinder Sahota